This AI trading robot from Day Trader ($2K per position): Medium Volatility Stocks for Active Trading (TA&FA), was a top performer in our robot factory over a month, generating 7.11% for OCGN.
ALX Oncology Holdings (ALXO) experienced a significant gain of 25% this month, positioning it as a top performer within the biotechnology industry.
Bellus Health (BLU) stock experienced an unprecedented one-day volume growth, resulting in a 631% increase compared to its 65-Day Volume Moving Average (65-DVMA).
This AI trading robot "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)", was one of the best in our robot factory, generating a 7.12% gain for OCGN over the course of the previous week.
POINT Biopharma Global Inc. (PNT) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. The company is set to report its earnings on March 24, and analysts are expecting a significant drop in earnings per share. According to analysts' estimates, the company's earnings per share are expected to fall...
Over the last three months, Editas Medicine (EDIT) has been a top loser in the biotechnology industry, falling by 18.5% to $8.37 per share. This information was gathered by A.I.dvisor, which analyzed 968 stocks in the biotechnology industry for the 3-month period ending March 17, 2023, and found that 60.19% of them demonstrated a downtrend, while only 39.81% exhibited an uptrend. However,...
On March 01, 2023, BridgeBio Pharma (BBIO) experienced a significant shift in its stock performance as the 50-day moving average moved above the 200-day moving average. This is known as a "golden cross" in technical analysis and is often considered a bullish signal for the stock's future performance. This news comes just days after BBIO's stock soared 52% following positive results from a...
Kala Pharmaceuticals (KALA) recently reported its fourth-quarter earnings, which missed estimates, causing some concern among investors. The company reported a loss of $0.32 per share, missing the consensus estimate of a loss of $0.29 per share. Despite the miss, the company's revenue beat expectations, coming in at $14.6 million compared to the expected $13.8 million. The Q4 earnings miss is...
Chemomab Therapeutics Ltd shares jumped on Tuesday, after it reported topline results from its Phase 2a trial assessing CM-101 in non-alcoholic steatohepatitis (NASH) patients. While the trial met its primary endpoint of safety and tolerability, CM-101 achieved reductions in secondary endpoints that include liver fibrosis biomarkers and physiologic assessments measured at baseline and week...
The U.S. Food and Drug Administration (FDA) approved TG Therapeutics Inc's Briumvi – a monoclonal antibody for treating patients with relapsing forms of multiple sclerosis (RMS). Briumvi is the first and only anti-CD20 monoclonal antibody approved for RMS that can be administered in a one-hour infusion following the first dose. The approval by the FDA may help offset the headwind to the...
Alzamend Neuro Inc .has partnered with the Miller School of Medicine, Interdisciplinary Stem Cell Institute at the University of Miami for its Phase 1/2A trial of ALZN002. ALZN002 is a patented immunotherapy method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to combat Alzheimer’s. On October 5, Alzamend announced the addition of healthy adult subject to its...
Signals from Pattern Search Engine Tickeron is bringing high-powered Artificial Intelligence (A.I.) technology to the retail investment community that, in our opinion, rivals the technology and approach used at major Wall Street firms. The Ph. D founders of Tickeron have spent several years researching and building an Artificial Intelligence-based search engine that allows active investors to...
Avid Bioservices posted adjusted earnings of $0.04 per share for the quarter ending July 2022, exceeding the Zacks Consensus Estimate of $0.03 per share. Earnings were $0.10 per share in the year-ago quarter. Revenues of $36.69 million for the quarter also topped the Zacks Consensus Estimate by 7.92%. The figure is also higher than year-ago period’s $30.75 million. The current consensus EPS...
RVL Pharmaceuticals plc. announced its preliminary second quarter FY22 sales from Upneeq of $8.4 million. The figure represents a +42% growth sequentially. Upneeq is an approved ophthalmic solution for droopy eyelids. The company also mentioned that it had received orders from approximately 2,200 cumulative unique medical aesthetics practices from February through June of 2022. CEO Brian...
BioNTech SE reported growth in earnings and revenue for the fourth quarter, driven by the Covid-19 vaccine it produces in partnership with Pfizer Inc. The company also announced its program for repurchasing shares of up to $1.5 billion over the next two years. The company posted net profit of 3.17 billion euros ($3.51 billion) for the last quarter of the year, up from EUR3.66 million a year...
Moderna and Pfizer shares climbed, after the U.S. Food & Drug Administration authorized the use of a second shot of Covid boosters developed by the pharma companies. According to the FDA, adults over the age of 50, as well as those with compromised immune systems, can receive a booster dose of either the Pfizer or Moderna vaccine at least four months after receiving the first. Peter Marks,...
Moderna posted fourth quarter earnings that surpassed expectations. The pharma company also boosted its full-year revenue outlook for Covid vaccine sales. and unveiled a new $3 billion share repurchase plan. Moderna’s diluted GAAP earnings came in at $11.29 per share for the three months ending in December, beating the Street expectations of $9.90 per share. It incurred a loss of -69 cents...
Iterum Therapeutics plc said that it will not get approval for the current form of its new drug application for oral sulopenem.
According to the Food and Drug Administration (FDA), additional data are required and the company should conduct at least one more well-controlled clinical trial for its treatment of adult women with uncomplicated urinary tract infections.FDA mentioned that it is willing to work with Iterum on the design of clinical trials in order to address the issues the FDA identified.
However, Iterum CEO Corey Fishman said the company is “disappointed in this outcome and believe that the data package submitted was adequate for the approval of oral sulopenem,” .
Myron Holubiak, president and chief executive mentioned that this would be the third recommendation by the DMC supporting the continuation of the Mino-Lok trial.He said the outcome indicates that “based on our predefined parameters, it would be possible to achieve our primary endpoint by continuing the trial as planned, and is an encouraging signal when combined with the results of our prior studies.